After a firm rejection of its buyout offer, Alere Inc. (NYSE:ALR) has started pleading to the sensibilities of Scottish competitor Axis-Sheild’s shareholders. This is not the first time the two firms have traded statements since Alere first offered its buyout in June.
Integra LifeSciences
Integra LifeSciences completes acquisition of Ascension Orthopedics
Integra LifeSciences Completes Acquisition of Ascension Orthopedics
PLAINSBORO, N.J., Sep 26, 2011 (GlobeNewswire via COMTEX) — Integra LifeSciences Holdings Corporation IART -1.26% today announced the closing of its previously announced acquisition of Ascension Orthopedics, Inc. (“Ascension.”) Ascension, based in Austin, Texas, develops and distributes a complementary range of implants for the shoulder, elbow, wrist, hand, foot and ankle.
“The acquisition of Ascension expands our platform in the fast-growing extremities space and provides us with access to the $600 million shoulder market,” said Stuart Essig, Integra’s Chief Executive Officer.
Is J&J in the hunt for Boston Scientific? | Acquisitions Roundup
Could the amicable deal between bitter rivals Johnson & Johnson (NYSE:JNJ) and Boston Scientific (NYSE:BSX) over Michael Mahoney leaving J&J to helm BSX signal an upcoming acquisition?
Opinions are divided on Wall Street, with at least one analyst wondering if a deal could be in the works and others casting doubt on the speculation.
Integra LifeSciences Announces Agreement to Acquire Ascension Orthopedics
PLAINSBORO, N.J. and AUSTIN, Texas, Sept. 12, 2011 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) and Ascension Orthopedics, Inc. (“Ascension”) today announced an agreement for Integra to acquire Ascension, a provider of high quality, innovative products for the foot, hand and shoulder markets, for approximately $65 million in cash, subject to adjustments. When combined with Integra’s legacy business, the products will represent approximately 45% of Integra’s Orthopedics revenues.
Recall hurts Haemonetics in its first quarter 2012 | Earnings Roundup
Blood management solutions giant Haemonetics Corp.’s (NYSE:HAE) first quarter 2012 financials saw a slide in sales and revenue driven by the voluntary recall of its OrthoPAT autotransfusion device.
Neoprobe sells radiation detection sector to Devicor | Acquisitions roundup
Cancer diagnostics firm Neoprobe Corp. (NYSE:NEOP) sold its Gamma Detection Systems sector to Devicor Medical Products Inc. in a deal that’s worth up to $50 million.
Devicor, based in Pleasant Valley, Wis., agreed to pay $30 million up front and up to $20 million in royalty payments.
Dublin, Ohio-based Neoprobe will get the full royalty payment if Devicor tops $21 million in sales of the devices in the next five years.
FDA approves spine sealant from Covidien | Regulatory roundup
Here’s a roundup of companies announcing clearances and approvals from the FDA and foreign regulatory agencies. Check out MassDevice’s compilation of the latest regulatory news for additional clearances and approvals.
Integra LifeSciences recalls brain catheter
Integra LifeSciences Corp. issued a global recall of its NeuroBalloon catheter.
The Plainsboro, N.J.-based holding company said it received a total of eight complaints, all from outside the U.S., regarding the inflation or deflation of the device.
Integra distributed 1,924 units in the U.S. and internationally, and it notified distributors and customers of the intracranial device about the possible defect July 2, the company said.